Novo Nordisk challenge for controlling prices in Economic recession

 Economic recession made a big pressure on the big brands and businesses. Novo Nordisk with Multi branches and multi international products that support global market is now under global economic recession pressure.

The thing that made a economical pressure on all sectors from R&D to the Production line. 

This economic challenge will impacts products prices in the global market. The thing that may exit the product from healthcare basket in the next 10 days. A big damage for Novo Nordisk brands in short term that may exit Novo Nordisk from top list of biotechnology companies in the global ranking.

Novo Nordisk challenge with Energy for 2022

 Novo Nordisk is a famous bio pharmaceutical brand in global market, but there are challenges against this brand for next 5 years.

Russia's invasion of Ukraine made a big challenge for European countries. Russia started a military invasion and for controlling global response to the war crimes in Ukraine use Oil and gas as a political leverage for returning back to the global community.

Global response to the war crimes in Ukraine was heavy sanctions that paralyzed Russia's economy. Russia's next movement was banning access of European countries to the Asian Energy market, the thing that in short term made a big political and economical pressure on the markets.

One of the energy consuming and heavy high tech industries in Denmark is Novo Nordisk. This company based on the high tech molecular solutions for curing disease become a qualified high trust brand in the market, but there are a big energy challenge for this company next 5 years.

Russia's policy for stopping NATO Partnership ally failed and Sweden and Finland Joined to this military ally, but now there are big political challenge in the market.

First of all, Russia's policy for banning access of European power to the Energy market. Second, China's policy for COVID19 lock down that damage the chains of supply. This will made a delay in production cycle. The big challenge that is a threaten against Brand and employee of this company in mid term.

How China war will impacts Novo Nordisk

 China economic policy for last decades were penetrating through global community economically and using multiple strategies to achieving a share from global market such as Dumping, Copying industrial design and patents.

Economic workers, Low prices and powerful industries made China one of the pioneer suppliers of Biotechnology products and pharmaceutical primary materials.

Novo Nordisk known as a pioneer biotech company in the global ranking, became one of the customers of other countries primary material. The thing that helped China understanding the needs of market and become one more powerful.

China Taiwan military conflict countdown started for 2022, The thing that is a big danger for chains of supply in the Europe and America. Novo Nordisk economical challenge with this war will be serious and soon may damage existence of FDA approved products in the global market.

The thing that is a big damage for stocks price and share holders. Novo Nordisk branding will face big challenge and this will lead to the decrease of penetrating rate through the market. 

In other hands, price of products will increase and some products will enter to the luxury baskets and become luxury cure methods. It seems that Lars Fruergaard Jørgensen should be ready for a big economic recession in the company and choosing a new strategy for short term.

Short review about Novo Nordisk CEO: Lars Fruergaard Jørgensen

 Novo Nordisk is one of the pioneer biopharmaceutical and biotechnology corporation in the global ranking. This company with multi branch policy all around the world hire about 48478 employee and develop new Cure methods based on the molecular solutions. 

Novo Nordisk recognized by Diabetic cure solution all around the world, but this company is one pioneer molecular developer for diseases.

Lars Fruergaard Jørgensen as a CEO of Novo Nordisk born on 1966 in Denmark. He has master science of Finance and business management from Aarhus University. His salary in Novo Nordisk is about 5,424,793 USD annually.